Literature DB >> 29753168

Serum TIMP1 and TIMP2 concentration in patients with different grades of meningioma.

Farhad Mashayekhi1, Alia Saberi2, Sohail Mashayekhi2.   

Abstract

OBJECTIVE: Meningiomas are common primary brain tumors that constitute about 13% of all intracranial tumors. Matrix metalloproteinase-9 (MMP-9) is able to degrade the extracellular matrix and basement membrane leading to cancer cell invasion and metastasis. MMPs are specifically inhibited by a family of small extracellular proteins known as the tissue inhibitors of metalloproteinases (TIMPs). The objective of this project was to evaluate serum concentration of TIMP-1 and TIMP-2 in patients with different grades of meningioma. PATIENTS AND METHODS: Ninety samples from different stages of patients with meningitis (42 cases of grade I, 28 grade II, 20 grade III) and 51 samples from normal healthy were included in this study. Total protein concentration (TPC) and the level TIMP-1 and TIMP-2 serum were determined by Bio-Rad protein assay based on the Bradford dye procedure and enzyme-linked immunosorbent assay (ELISA), respectively.
RESULTS: No significant change in the TPC was seen in the serum of patients with meningioma when compared with normal controls. Results obtained demonstrated that all serum samples presented TIMP-1 and TIMP-2 expression, whereas, starting from grade I to III meningiomas, a significant decrease of TIMP-1 and TIMP-2 expression was observed as compared to controls.
CONCLUSION: The results of this study show that a low expression of TIMP1 and TIMP2 is correlated with advanced stages of meningioma. It is also concluded that the detection of serum TIMP1 and TIMP2 may be useful in classifying different grades of meningioma.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Concentration; Meningioma; Serum; TIMP-1; TIMP-2

Mesh:

Substances:

Year:  2018        PMID: 29753168     DOI: 10.1016/j.clineuro.2018.05.001

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  5 in total

1.  miR-497 and 219 in blood aid meningioma classification.

Authors:  Ahmed Abdelrahman; Caterina Negroni; Felix Sahm; Claire L Adams; Tadeja Urbanic-Purkart; Michael Khalil; Raffaellla Vergura; Cristina Morelli; Clemens Oliver Hanemann
Journal:  J Neurooncol       Date:  2022-09-08       Impact factor: 4.506

2.  Total DNA methylation as a biomarker of DNA damage and tumor malignancy in intracranial meningiomas.

Authors:  Anna-Maria Barciszewska
Journal:  BMC Cancer       Date:  2020-06-03       Impact factor: 4.430

3.  Comprehensive analysis of expression, prognosis and immune infiltration for TIMPs in glioblastoma.

Authors:  Jinkun Han; Yajun Jing; Fubing Han; Peng Sun
Journal:  BMC Neurol       Date:  2021-11-15       Impact factor: 2.474

Review 4.  Molecular neuropathology of brain-invasive meningiomas.

Authors:  Niklas von Spreckelsen; Christoph Kesseler; Benjamin Brokinkel; Roland Goldbrunner; Arie Perry; Christian Mawrin
Journal:  Brain Pathol       Date:  2022-03       Impact factor: 6.508

Review 5.  Updated Systematic Review on the Role of Brain Invasion in Intracranial Meningiomas: What, When, Why?

Authors:  Lara Brunasso; Lapo Bonosi; Roberta Costanzo; Felice Buscemi; Giuseppe Roberto Giammalva; Gianluca Ferini; Vito Valenti; Anna Viola; Giuseppe Emmanuele Umana; Rosa Maria Gerardi; Carmelo Lucio Sturiale; Alessio Albanese; Domenico Gerardo Iacopino; Rosario Maugeri
Journal:  Cancers (Basel)       Date:  2022-08-27       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.